Description:
Micafungin sodium (FK 463 sodium) is an antifungal agent which inhibits 1, 3-beta-D-glucan synthesis.
In Vitro:
Micafungin (10 mg/mL) phenotypicly decreases the formation of biofilm in most of the isolates. For all the genes tested, the levels of mRNA transcription are also decreased significantly in micafungin-treated samples cf. their untreated counterparts. The combination of micafungin and KB425796-C is fungicidal and markedly reduces the number of CFU, in contrast to the fungistatic effects (no reduction in CFU) observed at all examined time points when each drug is used alone.
In Vivo:
Micafungin (1 mg/kg) significantly prolongs survival compared with mice administered saline. Animals given a combination of micafungin (0.1 mg/kg) and KB425796-C (32 mg/kg) show a trend towards prolonged survival in comparison with those treated with micafungin (0.1 mg/kg) alone. In the livers of micafungin-treated mice, the number of CFUs decreases, although the clearance effect is less than that found in the kidneys. Combination treatment with micafungin and KB425796-C results in a significant decrease in the number of CFUs compared with the treatment with micafungin alone at all examined doses. The clearance effect associated with KB425796-C in combination with micafungin is greater than that observed in AMPH-treated animals.
Related Prodcuts:
Echinocandin B; ECBN HCL; Micafungin FR-179642; Caspofungin Acetate; Pneumocandin B0; Caspofungin; Anidulafungin